astragaloside a has been researched along with glucagon-like peptide 1 in 1 studies
| Studies (astragaloside a) | Trials (astragaloside a) | Recent Studies (post-2010) (astragaloside a) | Studies (glucagon-like peptide 1) | Trials (glucagon-like peptide 1) | Recent Studies (post-2010) (glucagon-like peptide 1) |
|---|---|---|---|---|---|
| 675 | 5 | 573 | 9,484 | 1,208 | 6,374 |
| Protein | Taxonomy | astragaloside a (IC50) | glucagon-like peptide 1 (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, L; Jiang, J; Liu, H; Liu, J; Peng, L; Qiao, Y; Yan, X; Zhai, Y; Zhang, Z; Zhou, W | 1 |
1 other study(ies) available for astragaloside a and glucagon-like peptide 1
| Article | Year |
|---|---|
Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
Topics: Animals; Bile Acids and Salts; Ceramides; Diet, High-Fat; Fibroblast Growth Factors; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Intestines; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; RNA, Ribosomal, 16S; Saponins; Sterols; Triterpenes | 2022 |